National Cancer Institute (NCI)
NCI Public Inquiries Office
Building, 31, Room 10A03<br>31 Center Drive, MSC 2
793 articles with National Cancer Institute (NCI)
Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models
Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the National Institutes of Health (NIH)
Contract with National Cancer Institute will leverage data from Geisinger's MyCode Community Health Initiative
BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 With National Cancer Institute
BryoLogyx, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia (ALL) and lymphoma. The study, expected to start later this year, will be the first in patients to eva
T-Cure Bioscience Signs Exclusive Worldwide License With NCI for the Development of T Cell Receptor Therapy for Treatment of Solid Tumors
T-Cure Bioscience, Inc. announced that the Company has entered into an exclusive, worldwide license with the National Cancer Institute for intellectual property related to a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1, for the treatment of KK-LC-1-expressing malignancies, such as gastric, lung, and breast cancers.
EicOsis Awarded SBIR Grant from the NCI/NIH to Evaluate the Potential of Drug Candidate, EC5026, to Treat Cancer-associated Pain
EC5026 is an orally active potent small molecule that has been shown to be highly efficacious for pain relief of both inflammatory and neuropathic pain in a variety of animal species.
Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
Rafael will provide the compound for the study.
$1.86 Million Over Two Years to Develop Device for Isolating Exosomes
Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program
Kindred Biosciences, Inc. announced that it has been selected by the National Cancer Institute as one of three contractors in response to the solicitation for the PREVENT Cancer Preclinical Drug Development Program: Current Good Manufacturing Practice Production of Vaccines and Biologicals for Cancer Prevention.
RCCA Oncologists Help Write History with NCI's Recognition of John Theurer Cancer Center at Hackensack Meridian Health
When the National Cancer Institute accorded the John Theurer Cancer Center – part of Hackensack Meridian Health Hackensack University Medical Center – a rare and important designation this May, the move represented two historic firsts.
Precision Medicine Studies Underway to Enable Dynamic Monitoring of Disease Progression and Response to Treatment
The National Cancer Institute (NCI), an independent institute of the National Institutes of Health (NIH), was established in 1937 to provide for, foster and coordinate research relating to cancer.
AgilVax, Inc. announced that the company has triggered Phase II funding of $2 million from its Fast Track Small Business Innovation Research grant awarded by the National Cancer Institute.
The White House budget proposal released earlier this week that slashed spending on the National Institutes of Health and Medicare programs has put members of the administration, including Health and Human Services Secretary Alex Azar on the defensive.
National Cancer Institute Director Norman “Ned” Sharpless will take over the role as acting commissioner of the FDA while the White House seeks a permanent replacement for the outgoing Scott Gottlieb.
The president’s proposed spending plan cuts $4.5 to $5.5 billion from the current budget of the National Institutes of Health, about an 11 percent decrease from 2019.
Until recently, they were considered to be the three pillars of cancer treatment. Recent years have added a fourth pillar to surgery, radiation and chemotherapy—immuno-oncology.
City of Hope Awarded Lymphoma Specialized Programs of Research Excellence (SPORE) Grant from National Cancer Institute
The coveted grant of $12.5 million recognizes new and diverse approaches to lymphoma prevention, detection, diagnosis and treatment
12/14/2018It should come as no surprise that not all information on the internet is reliable. It’s a largely unregulated wild, wild west that allows for anyone to put up any content they wish to. Which can be a particular problem when it comes to health-related content.
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research
ABL, Inc (ABL), a global contract research and manufacturing service provider, is pleased to announce it was awarded the "Support for Research on Retroviral Pathogenesis, Treatment and Prevention" contract by the National Cancer Institute (NCI) to conduct studies that advance the development of effective AIDS vaccines and other preventive therapeutic modalities